6Teo M. Peritoneal-based malignancies and their treatment. Ann Aead Med,2010,39 ( 1 ) :54 - 57.
7Fushida S, Kinoshita J, Yagi Y, et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: A feasibility and pharmacokinetic study. Oncol Rep ,2008,19 (5) : 1305 - 1310.
8Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel : a gynecologic oncology group pilot study. J Clin Oncol, 1995, 13: 2961 - 2967.
9Morgan R J, James HD,Synold T, et al. Phase I trial of intraperitoneal docctaxel in the treatment of advanced malignancies primary confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res ,2003,9:5896 - 5901.
10Miyashiro I, Furukawa H, Sasako M, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positivc gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer, 2011,14:212 -218.
